At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 183 enrolled
Drug / intervention
Viagra (Sildenafil citrate)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Parallel Group, Flexible Dose Trial With A Double-Blind, Randomized, Placebo-Controlled Phase Followed By An Open-Label Phase To Assess The Impact Of Viagra On The Sexual Satisfaction Of Men With Mild Erectile Dysfunction
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Mar 10, 2006·Updated Feb 1, 2021
In Brief
A Phase 4 clinical trial evaluating Viagra (Sildenafil citrate) for Impotence. Completed, enrolled 183 participants across 26 sites.
Detailed Summary
Men's quality of life (QoL) is potentially affected by mild erectile dysfunction (ED) to the same extent as it is by moderate and severe ED. This study will provide controlled clinical data measuring efficacy, QoL parameters and satisfaction changes in men with mild ED treated with Viagra versus those treated with a placebo. With an open-label extension, this study will also provide all study subjects the opportunity to receive the active drug treatment for 6 weeks.
Study Details
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2005
First PostedMar 2006
Primary CompletionSep 2007
TodayJul 2026
First PostedMar 10, 2006
Enrollment StartNov 1, 2005
Primary CompletionSep 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 20.3 years ago
Interventions
Viagra (Sildenafil citrate)drug